What is Kidney Disease Market?
Previous hospital-based studies in Ethiopia showed a CKD prevalence of 18.2% and 23.8% and using modification of diet in renal diseases (MDRD) and Cockroft-Gualt (CG) equations, respectively, in patients with diabetes. Kidney disease means kidneys are damaged and can't filter as well. Kidney disease affected approximately 26 million American adults. Kidney damage may be caused by diabetes, high blood pressure, and various other chronic (long-term) conditions. The most common form of kidney disease is chronic kidney disease. It is a long term condition that doesn't improve over time.
The market study is being classified by Type (Chronic Kidney Disease and Acute Kidney Disease) and major geographies with country level break-up.
Taro Pharmaceutical Industries Ltd. (United States), Otsuka Pharmaceutical Co., Ltd. (Japan), Novartis International AG (Switzerland), Merck & Co. Inc. (United States), Sanofi S.A. (France), Amgen Inc. (United States), AstraZeneca plc (United Kingdom), Teva Pharmaceutical Industries Ltd. (Israel) and Bristol-Myers Squibb Company (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Fresenius Kabi AG (Germany) and Pfizer Inc. (United States).
The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that Global Players will contribute to the maximum growth of Global Kidney Disease market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Kidney Disease market by Type, Application and Region.
On the basis of geography, the market of Kidney Disease has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increased Population Suffering from Kidney Disease
- Increased Prevalence of Diabetes and Hypertension
- Technological Advancements in Medical Science
- Increased Research and Development Activities
- Growth in the Geriatric Population
- Growing Healthcare Industry Worldwide
- Stringent Government Rules and Regulations
Recently, India's biggest drugmaker Sun Pharmaceutical Industries has agreed to acquire Canadian pharmaceuticals firm Thallion Pharmaceuticals from Canada’s Bellus Health.
Key Target AudienceKidney Disease Treatment Providers, Emerging Professionals, Research Professionals and End-users
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase